ClinicalTrials.gg
Drug

Nacresertib clinical trials

studies test it
3
open now
0
in phase 3
0
first study started
2025

How each study uses nacresertib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Nacresertib
3

Studies by the year they started

3 studies that test it; most in 2026 (2)

Studies that test nacresertib, by start year
YearStudies
20251
20262

By phase

A phase 1/2 study counts in both.

Phase 1
3

Who runs them

Industry 3 · Other 0

AbbVie (3)

Related medicines

As reviewed, each with the page that says it.

Studies

Open first, then newest update. How each study uses nacresertib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 3

Codes

What other systems call nacresertib · ClinicalTrials.gg INT017282

  • UNII (FDA) MB3QBD4BE7NACRESERTIBOne source FDA
  • NCI Thesaurus C213407NacresertibOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.